Survival (S) impact of different factors in AIDS patients (pts): retrospective analysis (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Survival (S) impact of different factors in AIDS patients (pts): retrospective analysis (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A21 1993. Unique Identifier : AIDSLINE ICDB/93694421
Schmilovich A; Cahn P; Perez H; Gil Deza E; Huesped Foundation, Gascon 79, (1181) Buenos Aires, Argentina

Abstract: Between February 1983 and November 1992, 387 AIDS pts according to CDC classification system were assisted al Fernandez Hospital and Huesped Foundation. 296/387 had opportunistic infections (OI), 67/387 had Kaposi's sarcoma (KS) and 16/387 had non-Hodgkin's lymphomas (NHL) as initial disease. Eight pts were inevaluable. Age, sex, performance status (PS) according ECOG criteria, AZT treatment and CD4 level were evaluated for the whole group and stage and antineoplastic systemic treatment were also considered for neoplasias. Results: 49/387 still alive (12.6%); median survival (MS) of the whole group: 7.75 m (r1-49+ m). By univariate analysis (T test, Haenszel-Mantel) PS, AZT treatment and CD4 level correlates with MS. Results are presented in a table. By multivariate analysis (multiple regression), PS and AZT were the most significant factors to predict MS. Conclusions: (1) PS and AZT have linear correlation with S; (2) MS of good prognosis pts (3 factors) is 13.23 m; (3) MS of bad prognosis pts (3 factors) is 4.07 m; (4) PS must be included in all studies of AIDS pts.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/IMMUNOLOGY/ *MORTALITY *Cause of Death CD4-Positive T-Lymphocytes/IMMUNOLOGY Follow-Up Studies Human Leukocyte Count Retrospective Studies Survival Rate Zidovudine/THERAPEUTIC USE ABSTRACTKWDacquiredimmunodeficiencysyndrome/drugtherapy/immunology/KWDmortalityKWDcauseofdeathcd4-positivet-lymphocytes/immunologyfollow-upstudieshumanleukocytecountretrospectivestudiessurvivalratezidovudine/therapeuticuseabstract
931230
M93C0810

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .